Asset Details
Do you wish to reserve the book?
Pediatric T‐Lymphoblastic Leukemia With Aberrant B‐Cell Marker Expression: A Potential Role for Targeted Therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pediatric T‐Lymphoblastic Leukemia With Aberrant B‐Cell Marker Expression: A Potential Role for Targeted Therapy
Do you wish to request the book?
Pediatric T‐Lymphoblastic Leukemia With Aberrant B‐Cell Marker Expression: A Potential Role for Targeted Therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pediatric T‐Lymphoblastic Leukemia With Aberrant B‐Cell Marker Expression: A Potential Role for Targeted Therapy
2025
Overview
Background Expression of B‐cell antigens is rare in T‐lymphoblastic leukemia/lymphoma (T‐LBLL), and the significance is uncertain. Objective and Methods We present a pediatric case of acute leukemia characterized by the expression of T‐cell markers and CD19, as determined by multicolor flow cytometry (MFC). Next‐generation sequencing (NGS) revealed a SET::NUP214 gene fusion. The patient was treated with conventional intensive acute lymphoblastic leukemia (ALL) therapy. The end‐of‐induction evaluations showed significant residual disease. Results While the patient failed high‐risk T‐LBLL induction therapy, blinatumomab followed by decitabine and venetoclax induced a morphologic remission. He then underwent a bone marrow stem cell transplant (BMSCT) and achieved a complete molecular remission. Conclusions This case illustrated the importance of integrating MFC analysis with NGS data to provide individualized patient treatment. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.
